Navigation Links
Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Date:10/28/2008

to HIV infection.

"These data provide good support for the evaluation of our first ZFN-based ZFP Therapeutic in man," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "It was observed more than ten years ago that individuals carrying the natural CCR5-delta32 mutation were highly resistant to infection by HIV. Consequently, a variety of small molecule and antibody approaches have been tested as potential therapeutics. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. We believe that our ZFN technology provides an approach that circumvents the dosing and potential toxicity issues of a systemic therapy. By specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs, we can generate a population of R5-tropic HIV-resistant T-cells.

We have shown that these ZFN-modified human cells are made permanently resistant to infection by HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections characteristic of AIDS and HIV itself. The modified cells exhibited the expected properties of normal CD4 T-cells. These data also demonstrate that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic. We intend to file an investigational new drug (IND) application for this ZFP Therapeutic this year and begin a clinical trial as soon as possible."

Data Reported in the ICAAC/IDSA Presentation

The reported results demonstrate that a one-time exposure to CCR5-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
4. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
5. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
6. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
7. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
8. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
9. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
10. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
(Date:8/26/2015)... HONG KONG , Aug. 26, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... Holdings Limited ("MO2"), an entity wholly owned by Mr. ... the Company, has acquired the outstanding shares (the "Shares") ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... 26 in Kansas City. , ... Rockville, MD (PRWEB) ... Scientific Meeting (ASM) will be held in Kansas City, Mo., September ... the USP experts responsible for establishing internationally recognized standards for prescription ...
... Oncology Specialty, LP, the,state-of-the-art pharmaceutical distribution center of ... from the National,Safety Council for its outstanding safety ... who produce the "best of the best",in safety ... report,days away from work resulting from workplace injuries ...
... 3 Inverness Medical,Innovations, Inc. (Amex: IMA ... products for the consumer and professional markets, today,announced ... and Jon Russell, Vice President, Finance, are scheduled ... Conference on,Tuesday, September 9th, 2008 in New York. ...
Cached Biology Technology:USP's 2008 Annual Scientific Meeting to Convene Scientific Experts from Around the World 2USP's 2008 Annual Scientific Meeting to Convene Scientific Experts from Around the World 3US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award 2
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... the traditional summer treat associated with Wimbledon could ... Scientists at the University of Warwick have been ... cardiovascular health, particularly around how they prevent the ... Paul Thornalley from Warwick Medical School heads the ...
... and significance of the biological clocks in polar planktonic ... entitled PolarTime starting July 1st, 2012. It is one ... Association. PolarTime, coordinated by the Alfred Wegener Institute for ... to five years with approximately three million euros from ...
... been made in most developing countries to meet the ... who suffer from hunger by 2015 compared with 1990 ... children,s height and weight, published today in the ... five has improved overall since 1985, one in five ...
Cached Biology News:Just a question of time? 2Just a question of time? 3Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 2Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 3
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 30 isolations. The kit provides a ... apoptotic cells from normal c lture using ... is a Ca2+-dependent phospholipid binding protein with ... Cell Isolation Kit provides a simple and ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: